Takeda Pharmaceutical Company Limited

TAKNYSEHealthcare● Active

$15.79

+$0.19(+1.19%)

Market Cap$49.9B

P/E Ratio—

52W High$18.9

52W Low$12.99

Avg Volume3.0M

Open$15.74

Beta0.09

Cash on Hand Financials Revenue

Takeda Pharmaceutical Company Limited (TAK) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

TAK · cash on hand · updated Mar 31, 2026

Core cash position

as of Mar 31, 2026

Cash & Short-Term Investments (CCE + ST Investments)

$597.63B▲ +47.3% vs prior year

FY · as of Mar 31, 2026 · Reported in JPY

Cash & Cash Equiv. (CCE)

$597.63B

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+47.3%

vs prior fiscal year

Latest Quarter

$597.63B

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in JPY

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: March 31, 2026

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$597.63BCash on Hand

Total Debt$4.90TTotal Debt

Net Cash / Net Debt−$4.31TNet Debt Position

Cash vs Debt Ratio

Cash 11%Takeda Pharmaceutical Company Limited cash as % of market cap: 1198.25%% · MCap $50BDebt 89%

Takeda Pharmaceutical Company Limited carries a net debt position of $4.31T. Total debt ($4.90T) exceeds cash on hand ($597.63B). Takeda Pharmaceutical Company Limited cash vs debt ratio: 11% cash / 89% debt.

Net Cash = Cash & ST Investments − Total Debt$597.63B − $4.90T = −$4.31T

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

TAK annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

TAK cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Mar 31, 2026LatestFY$597.63B+47.3%

Mar 31, 2025FY$405.59B-14.2%

Mar 31, 2024FY$472.89B-14.6%

Mar 31, 2023FY$553.70B-36.7%

Mar 31, 2022FY$875.00B-12.7%

TAK cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

TAK vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

Takeda Pharmaceutical Company LimitedYOU

TAK

$597.63B$50B1197.5%

100%

UnitedHealth Group Incorporated

Eli Lilly and Company

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Takeda Pharmaceutical Company Limited (TAK) cash on hand as of March 31, 2026 is $597.63B, comprising $597.63B in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Takeda Pharmaceutical Company Limited cash and short-term investments on the balance sheet (10-K filing). Also referred to as Takeda Pharmaceutical Company Limited cash reserves or cash position.

Takeda Pharmaceutical Company Limited annual cash on hand history shows increased +47.3% in 2026: increased +47.3% in 2026. Takeda Pharmaceutical Company Limited cash reserves in 2026 reflect the company's capital allocation strategy.

Takeda Pharmaceutical Company Limited carries total debt of $4.90T against cash of $597.63B, resulting in a net debt position of -$4.31T. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

TAK cash on hand · 5 questions

As of March 31, 2026, Takeda Pharmaceutical Company Limited (TAK) has $597.63B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $597.63B in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $597.63B. Data sourced from the annual 10-K filing via FMP.

TAK cash on handTAK cash reservesTAK cash 2026how much cash does TAK have

▸ Source: FMP /balance-sheet-statement · US GAAP · Takeda Pharmaceutical Company Limited · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: March 31, 2026